<DOC>
	<DOCNO>NCT02504294</DOCNO>
	<brief_summary>A phase 3b study subject receive Epogen compare dose algorithm Hospira Epoetin Standard Care Epogen .</brief_summary>
	<brief_title>A Phase 3b Study Erythropoietin Drugs Using Specified Dosing Algorithm Patients With Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description>Primary Objective : To evaluate switch Epogen Epoetin Hospira maintenance hemoglobin level anemic chronic kidney disease ( CKD ) subject hemodialysis use specify algorithm dose erythropoietin stimulating agent ( ESA ) . Secondary Objective : To evaluate switch Epogen Epoetin Hospira dose ESA anemic CKD subject hemodialysis use specify algorithm dose ESA . Exploratory Objectives : To generate hypothesis regard maintenance hemoglobin level , dose ESA , intravenous ( IV ) iron dosing requirement , transferrin saturation ( TSAT ) level ferritin level associate switch Epogen Epoetin Hospira anemic CKD subject hemodialysis use specify algorithm dose ESA dose IV iron , standard care .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion Criteria Subjects eligible enter study meet follow criterion : 1 . Adult female male subject ; age ≥ 18 year . 2 . End stage renal disease subject treat incenter modality hemodialysis ≥ 120 day . 3 . Diagnosed anemia . 4 . Administered routine Epogen therapy least 16 week IV route treatment anemia use Epogen version FMCNA dose algorithm ESA , miss 3 prescribed dos Epogen within 12 week prior randomization . 5 . Currently use IV Epogen version ESA dose algorithm cMAB 5 ( inclusive version 5.0 , 5.1 , … ) anemia management . 6 . Receiving hemodialysis clinic use FMCNA dose algorithm IV iron FMCNA standard care treatment iron replacement . Exclusion Criteria Subjects meet follow criterion ineligible enter interventional cohort : 1 . Subjects unable provide sign date informed consent clinical research study . 2 . As determined Investigator , female subject child bear potential agree use highly effective method contraception . 3 . Any condition determine investigator would place subject increase risk , preclude subject 's full compliance study procedures visit . 4 . Female subject know found , pregnant lactating . 5 . Subjects candidate ESA therapy per label warning list package insert Epogen and/or contraindication Epoetin Hospira list Investigators ' Brochure ; know positive test antirhEPO antibody . 6 . Treatment investigational drug within 30 day prior randomization throughout clinical trial . 7 . Diagnosed concurrent condition could lead greaterthannormal loss blood , include limited : Menorrhagia , peptic ulcer disease , gastrointestinal bleeding , blood dyscrasia , hemoglobinopathy Use anticoagulation therapy , include warfarin target international normalized ratio ( INR ) 2 great Antiplatelet therapy ( e.g . aspirin clopidogrel ) permit , heparin give hemodialysis . Lowdose warfarin permit defined presence least two INR value less equal 1.5 120 day prior enrollment value exceed 1.5 time 120 day prior enrollment . Subjects start warfarin know INR goal 2.0 great receive treatment study drug , follow visit continue . Subjects warfarin meet criterion enter study terminate INR &gt; 2.0 discover INR available 60 day . 8 . History transfusion blood product past 3 month , 2 transfusion past 1 year ; donate lose &gt; 475 mL blood volume ( include plasmapheresis ) past 3 month . 9 . Subjects currently receive long act ESA , receive long acting ESA 16 week prior study randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>